Dissanaike Sharmila 4

What Happened
Dissanaike Sharmila, a director of Heron Therapeutics (HRTX), was granted 53,960 restricted stock units (RSUs) on January 30, 2026. The Form 4 reports the acquisition at $0.00 per share (total $0) because this was an award, not an open-market purchase or sale. The RSUs vest in full on January 30, 2027 and each unit represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-01-30; Filing date: 2026-02-03.
• Transaction type: A = Award/Grant (restricted stock units). Price reported: $0.00; shares granted: 53,960.
• Vesting and conversion: Per footnote, RSUs vest in full on 2027-01-30; each RSU converts to one share upon vesting (contingent).
• Shares owned after transaction: Not stated in the provided excerpt of the filing. Check the full Form 4 for total holdings.
• Timeliness: The grant date was 2026-01-30 and the Form 4 was filed 2026-02-03. Form 4s are normally due within two business days of the transaction; this filing was submitted several days after the grant (review the SEC filing for any explanatory codes or exceptions).

Context
RSU grants are compensation awards and do not involve an immediate cash purchase or sale; they only convert to actual shares if and when they vest. Such grants are common for directors and executives as retention/compensation and are not by themselves a clear bullish or bearish signal.